CN114980974A - 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽 - Google Patents
含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽 Download PDFInfo
- Publication number
- CN114980974A CN114980974A CN202080085549.9A CN202080085549A CN114980974A CN 114980974 A CN114980974 A CN 114980974A CN 202080085549 A CN202080085549 A CN 202080085549A CN 114980974 A CN114980974 A CN 114980974A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- seq
- acid sequence
- isvd
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945391P | 2019-12-09 | 2019-12-09 | |
| US62/945,391 | 2019-12-09 | ||
| EP20305064 | 2020-01-27 | ||
| EP20305064.6 | 2020-01-27 | ||
| PCT/EP2020/085304 WO2021116182A1 (en) | 2019-12-09 | 2020-12-09 | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114980974A true CN114980974A (zh) | 2022-08-30 |
Family
ID=73793214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080085549.9A Pending CN114980974A (zh) | 2019-12-09 | 2020-12-09 | 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20210188965A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4072674A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7641968B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102984686B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114980974A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020400938A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022010223A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163910A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2022008813A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL293548A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007035A (cg-RX-API-DMAC7.html) |
| MY (1) | MY208649A (cg-RX-API-DMAC7.html) |
| TW (2) | TWI861302B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021116182A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026067440A1 (zh) * | 2024-09-29 | 2026-04-02 | 四川科伦博泰生物医药股份有限公司 | Tslp/il-13双特异性抗体及其用途 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| CN114980974A (zh) | 2019-12-09 | 2022-08-30 | 艾伯霖克斯公司 | 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽 |
| WO2022063984A1 (en) * | 2020-09-25 | 2022-03-31 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
| CA3217029A1 (en) * | 2021-05-30 | 2022-12-08 | Biolojic Design Ltd. | Engineered dual binding antibodies and uses thereof |
| KR20250025381A (ko) | 2022-06-17 | 2025-02-21 | 아포지 바이오로직스, 인크. | 인터류킨 13에 결합하는 항체 및 사용 방법 |
| WO2024017915A1 (en) * | 2022-07-18 | 2024-01-25 | Ablynx N.V. | Cx3cr1-binding compounds, uses thereof and related methods |
| CN118005784A (zh) | 2022-11-08 | 2024-05-10 | 上海洛启生物医药技术有限公司 | 抗il-13长效纳米抗体序列及其应用 |
| US20240415974A1 (en) | 2022-12-23 | 2024-12-19 | Ablynx N.V. | Protein-based conjugation carriers |
| IL322519A (en) | 2023-02-17 | 2025-10-01 | Ablynx Nv | Polypeptides that bind to the neonatal fc receptor |
| AU2024247861A1 (en) | 2023-03-24 | 2025-11-06 | Sanofi | Asthma treatment by blocking il-13 and tslp |
| EP4435005A1 (en) | 2023-03-24 | 2024-09-25 | Sanofi | Asthma treatment by blocking il-13 and tslp |
| EP4731663A2 (en) * | 2023-06-22 | 2026-04-29 | Paragon Therapeutics, Inc. | Antibodies that bind interleukin 13 and tslp or tslpr and methods of use |
| AR133647A1 (es) | 2023-08-25 | 2025-10-22 | Proteologix Us Inc | Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos |
| AR134101A1 (es) * | 2023-10-12 | 2025-12-03 | Innovent Biologics Suzhou Co Ltd | Anticuerpos anti-tslp y usos de los mismos |
| WO2025209486A1 (en) * | 2024-04-02 | 2025-10-09 | Keymed Biosciences (Chengdu) Co., Ltd. | Antibodies targeting il-13 and tslp and uses thereof |
| WO2026041740A1 (en) | 2024-08-21 | 2026-02-26 | Sanofi | Treatment of high-risk asthma by blocking il-13 and tslp |
| WO2026055143A2 (en) * | 2024-09-03 | 2026-03-12 | Attovia Therapeutics, Inc. | Il13-binding polypeptides and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160264658A1 (en) * | 2015-03-11 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | TSLP Binding Proteins |
| CN108473561A (zh) * | 2015-11-27 | 2018-08-31 | 埃博灵克斯股份有限公司 | 抑制cd40l的多肽 |
| CN109887553A (zh) * | 2019-01-29 | 2019-06-14 | 杭州纽安津生物科技有限公司 | 针对肿瘤靶向药物耐药位点的多肽疫苗及其设计方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| AU2007237501A1 (en) | 2006-04-14 | 2007-10-25 | Ablynx N.V. | DP-78-like nanobodies |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン.ヴェー. | Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| US20100113339A1 (en) * | 2006-09-08 | 2010-05-06 | Ablynx N. V. | Serum albumin binding proteins with long half-lives |
| AR064333A1 (es) * | 2006-12-14 | 2009-04-01 | Schering Corp | Anticuerpo anti-tslp de diseno |
| CA2744588A1 (en) * | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Ligands that bind il-13 |
| CA3141978A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| LT3466972T (lt) | 2011-06-23 | 2026-06-25 | Ablynx Nv | Serumo albuminą surišantys baltymai |
| LT3248986T (lt) | 2014-05-16 | 2022-03-25 | Ablynx Nv | Imunoglobulino kintami domenai |
| HUE057241T2 (hu) | 2015-11-13 | 2022-04-28 | Ablynx Nv | Javított, szérumalbumint kötõ immunoglobulin variábilis domének |
| US10544222B2 (en) * | 2015-11-18 | 2020-01-28 | Merck Sharp & Dohme Corp. | PD1/CTLA4 binders |
| AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| US11248057B2 (en) * | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| US11840569B2 (en) | 2016-11-16 | 2023-12-12 | Ablynx N.V. | T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta |
| WO2018104444A1 (en) | 2016-12-07 | 2018-06-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| EP3571224B1 (en) | 2017-01-17 | 2024-08-07 | Ablynx NV | Improved serum albumin binders |
| EP4442709A3 (en) | 2017-01-17 | 2024-12-25 | Ablynx NV | Improved serum albumin binders |
| KR20260100427A (ko) * | 2018-03-28 | 2026-06-29 | 오리오니스 바이오사이언시즈 인코포레이티드 | 이작용성 단백질 및 이의 작제물 |
| CN114980974A (zh) | 2019-12-09 | 2022-08-30 | 艾伯霖克斯公司 | 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽 |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
-
2020
- 2020-12-09 CN CN202080085549.9A patent/CN114980974A/zh active Pending
- 2020-12-09 IL IL293548A patent/IL293548A/en unknown
- 2020-12-09 JP JP2022534664A patent/JP7641968B2/ja active Active
- 2020-12-09 TW TW109143498A patent/TWI861302B/zh active
- 2020-12-09 AU AU2020400938A patent/AU2020400938A1/en active Pending
- 2020-12-09 BR BR112022010223A patent/BR112022010223A2/pt unknown
- 2020-12-09 MX MX2022007035A patent/MX2022007035A/es unknown
- 2020-12-09 TW TW113137609A patent/TW202530257A/zh unknown
- 2020-12-09 WO PCT/EP2020/085304 patent/WO2021116182A1/en not_active Ceased
- 2020-12-09 US US17/115,906 patent/US20210188965A1/en not_active Abandoned
- 2020-12-09 KR KR1020227023385A patent/KR102984686B1/ko active Active
- 2020-12-09 EP EP20823785.9A patent/EP4072674A1/en active Pending
- 2020-12-09 MY MYPI2022002971A patent/MY208649A/en unknown
- 2020-12-09 CA CA3163910A patent/CA3163910A1/en active Pending
-
2021
- 2021-11-19 US US17/530,850 patent/US12492248B2/en active Active
- 2021-11-19 US US17/530,727 patent/US12384840B2/en active Active
- 2021-11-19 US US17/530,800 patent/US11840566B2/en active Active
-
2022
- 2022-06-24 CO CONC2022/0008813A patent/CO2022008813A2/es unknown
-
2025
- 2025-02-20 JP JP2025025563A patent/JP2025081540A/ja active Pending
- 2025-11-12 US US19/386,343 patent/US20260152549A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160264658A1 (en) * | 2015-03-11 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | TSLP Binding Proteins |
| CN108473561A (zh) * | 2015-11-27 | 2018-08-31 | 埃博灵克斯股份有限公司 | 抑制cd40l的多肽 |
| CN109887553A (zh) * | 2019-01-29 | 2019-06-14 | 杭州纽安津生物科技有限公司 | 针对肿瘤靶向药物耐药位点的多肽疫苗及其设计方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026067440A1 (zh) * | 2024-09-29 | 2026-04-02 | 四川科伦博泰生物医药股份有限公司 | Tslp/il-13双特异性抗体及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| US12492248B2 (en) | 2025-12-09 |
| MY208649A (en) | 2025-05-22 |
| US20220177564A1 (en) | 2022-06-09 |
| TW202136302A (zh) | 2021-10-01 |
| US20220177566A1 (en) | 2022-06-09 |
| KR102984686B1 (ko) | 2026-07-01 |
| EP4072674A1 (en) | 2022-10-19 |
| US20220177565A1 (en) | 2022-06-09 |
| CA3163910A1 (en) | 2021-06-17 |
| MX2022007035A (es) | 2022-06-23 |
| JP2023504914A (ja) | 2023-02-07 |
| US20260152549A1 (en) | 2026-06-04 |
| US20210188965A1 (en) | 2021-06-24 |
| JP7641968B2 (ja) | 2025-03-07 |
| KR20220123237A (ko) | 2022-09-06 |
| BR112022010223A2 (pt) | 2022-09-06 |
| WO2021116182A1 (en) | 2021-06-17 |
| TW202530257A (zh) | 2025-08-01 |
| AU2020400938A1 (en) | 2022-07-28 |
| CO2022008813A2 (es) | 2022-07-19 |
| US11840566B2 (en) | 2023-12-12 |
| IL293548A (en) | 2022-08-01 |
| US12384840B2 (en) | 2025-08-12 |
| TWI861302B (zh) | 2024-11-11 |
| JP2025081540A (ja) | 2025-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7641968B2 (ja) | Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド | |
| US11208476B2 (en) | Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP | |
| JP7817994B2 (ja) | Il-13およびox40lを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド | |
| CN114981300B (zh) | 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽 | |
| JP7719775B2 (ja) | TNFαおよびOX40Lを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド | |
| JP7842101B2 (ja) | IL-6およびTNF-αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド | |
| US12258394B2 (en) | IL-5 antibody, antigen binding fragment thereof, and medical application therefor | |
| CN114805572B (zh) | 抗原结合蛋白及其应用 | |
| CN116783214A (zh) | 包含靶向il-13和ox40l的免疫球蛋白单可变结构域的多肽 | |
| RU2836310C1 (ru) | Полипептиды, содержащие одиночные вариабельные домены иммуноглобулинов, нацеливающиеся на il-13 и tslp | |
| BR122024023752A2 (pt) | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que se ligam a il-13 e/ou tslp, método de produção e usos dos mesmos, ácido nucleico, composição e uso da mesma, e hospedeiro ou célula hospedeira | |
| CN116615453A (zh) | 包含靶向IL-6和TNF-α的免疫球蛋白单可变结构域的多肽 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |